CD4 and colitis: An alternative but less expensive colitis model for pharmacological testing of new drug candidates, in terms of required technical expertise and high yield of transferable cells for colitis induction, was developed by Kjellev et al. and was based on the transfer of CD4+CD25− T cells, a CD4+ subtype lacking Treg cells, to syngeneic immunodeficient mice [21].